Company OverviewPresentation is prepared for Skolkovo Foundation2012
Key Facts• Company status        Private Russian biotech company• Founded               2010• Our mission           Develo...
Pipeline                                                                                          Further                 ...
MM-D37K Summary• Product: chimeric peptide based on CPP platform technology for colorectal cancer (CRC)  treatment with po...
Market Overview (CRC)Colorectal cancer is a type of cancer characterized by neoplasia in the colon, rectum, or vermiform a...
Global CRC Market StructureGlobal market structure in monetary terms   Monoclonal antibodies    Pt based agents         To...
Russian Market (CRC)Colorectal cancer is taking third place by prevalence in the structure of all cancers (RussianOncology...
MM-D37K is a “chimeric” peptide:1) Transport sequence                                                             MM-D37K ...
MM-D37K (in vitro)• Fast speed of penetration into cells;• The dynamics of accumulation in normal and tumor  cells do not ...
MM-D37K (in vivo)Efficacy studies:• Activity against gastrointestinal cancers;• Additive effect with 5-fluorouracil• Route...
Pipeline Development                     1) Expansion of MM-D37K indicationsPancreatic cancer   Stomach cancer    Bladder ...
R&D Activities  Peptide screening based on:• Best energy binding with target protein CDK4(6) –Vina and Umbrella sampling m...
Publications• “Effect of metabolizable peptide p16INK4a on short-lived human tumor cultures”.Bozhenko VK, Kulinich TM, Iva...
Intellectual property      №             RU2435787* (issued)                EA201100464                 PCT/EA 2011/000343...
TeamChief Executive OfficerAndrey Boldyrev,- project management        experience    within   Russian    National   Union ...
AdvisersIgor Rodionov - Ph.D. in Bioorganic chemistry;- Deputy Head of the Laboratory of Peptide Chemistry- Branch of Shem...
Thank you for your attention   For more information, please contact:          Andrey Boldyrev, CEO              MetaMax, L...
Upcoming SlideShare
Loading in …5
×

MetaMax presentation for Skolkovo

1,341 views

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,341
On SlideShare
0
From Embeds
0
Number of Embeds
401
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

MetaMax presentation for Skolkovo

  1. 1. Company OverviewPresentation is prepared for Skolkovo Foundation2012
  2. 2. Key Facts• Company status Private Russian biotech company• Founded 2010• Our mission Developing and marketing innovative biopharmaceutical drugs targeting the most prevalent and dangerous systemic diseases• Main focus Oncology• Technology platform Cell-penetrating peptides (CPP)• Investors Maxwell Biotech Venture Fund• Partners  Maxwell Biotech Group  RVC  Skolkovo 2
  3. 3. Pipeline Further development Stage Lead Screening Preclinical Phase 1 Phase 2aProduct optimization MM-D37K Colorectal cancer Colorectal cancer MM-D37K Other indications Other indicationsNovel peptides2012 goals:• Receiving clinical trial permission for Phase 1/2a on patients with gastrointestinal cancers;• R&D activities — in silico, in vitro and in vivo screening and optimization 3
  4. 4. MM-D37K Summary• Product: chimeric peptide based on CPP platform technology for colorectal cancer (CRC) treatment with possible expansion to other cancer treatment indications;• Mechanism of action: activates apoptosis in cancer cells using cycline-dependent kinase inhibition mechanism;• Market potential: Global CRC market ~ $7 billion with unmet clinical need to decrease toxicity of current chemotherapy as well as to prolongate life of patients with metastatic forms of cancer; Russian CRC market- $60 million;• Competitive advantages: low peptide toxicity together with additive/synergiс effect with traditional chemotherapeutic agents;• In vitro and in vivo activity demonstrated in different tumor types;• Development status: preparing regulatory registration package to initiate clinical trials on patients with gastric cancers. 4
  5. 5. Market Overview (CRC)Colorectal cancer is a type of cancer characterized by neoplasia in the colon, rectum, or vermiform appendixCRC is one of the leading causes of all cancer deaths worldwide and accounts for more than 600 000 deathsevery year (WHO, 2011). 550 000 520 000 488 000 Number of new CRC cases diagnosed per yearGlobal CRC Market• Volume ~ $7 bln in 2011;• Forecast ~ $11.5 bln in 2017 ;• Drivers: population growth, increase in life expectancy, cancerogenic diet. 5
  6. 6. Global CRC Market StructureGlobal market structure in monetary terms Monoclonal antibodies Pt based agents Topoisomerase inhibitors Antimetabolite compounds 9% Bevacizumab 13% 31% 47% Panitumumab 13% Cetuximab 31% 3%“Gold standard” for current treatment metastatic colorectal cancer treatment- FOLFOX scheme:5-fluorouracil/ Leucovorin/ OxaliplatinCurrent colorectal cancer therapies remain very toxic and do not improve quality of life for patientswith metastatic cancer. 6
  7. 7. Russian Market (CRC)Colorectal cancer is taking third place by prevalence in the structure of all cancers (RussianOncology Center);Incidence• 50,000 people new cases diagnosed with CRC;• Incidence increasing over the last 10 years for over 14%;• Almost 60% of the disease is diagnosed in stage III - IV, when the treatment is difficult and not effective;Treatment• 240,000 patients in needed of treatment of colorectal cancer and colon;• The provision of necessary medicines - 5%;• Market volume - $60M 7
  8. 8. MM-D37K is a “chimeric” peptide:1) Transport sequence MM-D37K p16 Cell cycle2) Cytotoxic sequence cyclin D cancer cells p16 cyclin-dependent Apoptosis activation kinase 8
  9. 9. MM-D37K (in vitro)• Fast speed of penetration into cells;• The dynamics of accumulation in normal and tumor cells do not differ on the nature and rate of accumulation;• The peptide is able to cross the membrane in both directions;• It is shown that the greatest activity is typical for the p16-Antp vector (MM-D37K);• High efficacy against wide spectrum of cancer types;• Additive effect with etoposide, synergistic effect with taxol.Short-term human tumors:• The most sensitive lines — colorectal cancer, pancreatic cancer, kidney cancer, breast cancer, gastriccancer;• Increased level of induced apoptosis in lymphocytes of patients (chronic lymphocytic leukemia)compared with healthy lymphocytes. 9
  10. 10. MM-D37K (in vivo)Efficacy studies:• Activity against gastrointestinal cancers;• Additive effect with 5-fluorouracil• Route of administration — intravenousPharmacokinetic studies: HCT116, HCT116,• Accumulation in vascularised organs – control 11,5x13,5 mm MM-D37K 4,5x4,5 mmliver, spleen, lung and kidney;• Fast blood clearance: Typical MS spectra- Route of administration — intravenous- Method of detection- LC-MS (ESI-TOF)• Toxicity/safety studies:Up to 100 mg/kg – mice, rats and rabbits (both sexes)MM-D37K administration does not cause pathological changes in the brain, internal andendocrine organs, does not affect water and food consumption. 10
  11. 11. Pipeline Development 1) Expansion of MM-D37K indicationsPancreatic cancer Stomach cancer Bladder cancer Liver cancer Glioblastoma 2) R&D activities: a) New cell-penetrating sequences searching (in silico) Partner: Moscow State University - Mechanics and Mathematics Faculty b) New cytotoxic sequences searching (in silico) Partners: - Moscow State University – Biological Faculty (department of biophysics) - Moscow Institute of Physics and Technology 11
  12. 12. R&D Activities Peptide screening based on:• Best energy binding with target protein CDK4(6) –Vina and Umbrella sampling methods;• Conformation changes in target protein CDK4(6). Black — in vitro results of different p16 sequences (Fåhraeus R et al “Characterization of the cyclin- dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule” Oncogene. 1998 Feb 5;16(5):587-96.) Red — computer modeling results Possible commercialization results:• pipeline development — p16 protein sequence optimization;• pipeline/collaboration development — new sequences that inhibit “hot” targets;• custom services — new sequences that inhibit “hot” targets for biotech companies and big pharma. 12
  13. 13. Publications• “Effect of metabolizable peptide p16INK4a on short-lived human tumor cultures”.Bozhenko VK, Kulinich TM, Ivanov AV, Kudinova EA, Shishkin AM, Kharchenko VP.Vop. Onkol. 2009;55(4):451-4;• “Cytostatic and cytotoxic properties of chimeric peptides containing cyclin-inhibiting fragments”.Kulinich TM, Kharchenko VP, Filyasova EI, Shishkin AM, Bozhenko VK.Bull Exp Biol Med. 2008 Jan;145(1):37-40.;• “Cytotoxicity of chimera peptides incorporating sequences of cyclin kinases inhibitors”.Kharchenko VP, Kulinich VG, Lunin VG, Filiasova EI, Shishkin AM, Sergeenko OV, RiazanovaEM, Voronina OL, Bozhenko VK.Vopr Onkol. 2007;53(4):448-52;• 2 additional publications are coming soon:- Preclinical summary of MM-D37K;- Novel methods of molecular dynamics screening. 13
  14. 14. Intellectual property № RU2435787* (issued) EA201100464 PCT/EA 2011/000343 Priority date 29.09.2010 06.04.2011 06.04.2011 «Chimeric peptide and it’s «Pharmaceutical «Pharmaceutical composition pharmaceutical composition composition for Title for hyperproliferative disease for cancer disease hyperproliferative disease treatment» treatment» treatment» Inventor Bozhenko V.K. Bozhenko V.K. Bozhenko V.K. Applicant MetaMax, Ltd. MetaMax, Ltd. MetaMax, Ltd.* «Top-100 inventions in Russia» in 2011 year (Federal Institute of Industrial Property) Aggressive patent strategy based on R&D activities 14
  15. 15. TeamChief Executive OfficerAndrey Boldyrev,- project management experience within Russian National Union ofBusiness Angels;- experience as an expert on intellectual property in the area of ​"biotechnology" inthe FGU FIPS (Federal service for intellectual property, patent and trademark);- academic background with honors in biochemistry and professionalexperience in bioorganic chemistry in Institute of Bioorganic Chemistry (RussianAcademy of Science) Chief Scientific Adviser Vladimir Bozhenko, - Professor, PhD, MD, Honored Medical Doctor of the Russian Federation; - Head of Department of Pathology and Laboratory Diagnostics at the Russian Scientific Center of Radiology; - Member of Dissertation Council at the Russian Federal Research Center of Radiology (Rosmedtechnology); - author of more than 160 publications and 7 patents. 15
  16. 16. AdvisersIgor Rodionov - Ph.D. in Bioorganic chemistry;- Deputy Head of the Laboratory of Peptide Chemistry- Branch of Shemyakin and Ovchinnikov Institute ofBioorganic Chemistry (Russian Academy of Science);- Senior Lecturer, Associate Professor of Pushchino State University;- Research interests: peptide synthesis, optimization study of adverse reactions, development of newmethods for monitoring). Fine custom chemical synthesis of cyclic peptides, lipopeptides. Yaroslav Kholodov - Ph.D. in Physics and Mathematical Sciences; - Research Officer, Department of computational mathematics at the Moscow Institute of Physics and Technology; - Research interests: computer studies and modeling of high- performance computing systems for computer simulation of physical, chemical and biological processes.Company is actively uses Maxwell Biotech competencies including scientific, clinical and developmentassistance. 16
  17. 17. Thank you for your attention For more information, please contact: Andrey Boldyrev, CEO MetaMax, Ltd. tel: +7 (495) 411-6992 office 3.29, Alexander House, 1 Bolshaya Yakimanka str. Moscow, 119180, Russia boldyrev@metamax.biz

×